One of the most significant challenges that pharmacist entrepreneurs encounter is obtaining buy-in from their team members, particularly within the dynamic and regulated landscape of the healthcare industry.
The new drug Litfulo (ritlecitinib) has reached the Canadian market, while baricitinib (Olumiant) is now approved for alopecia areata and in a new higher-strength tablet.
The Ontario College of Pharmacists survey comes amid media stories of pharmacies imposing quotas on clinical services and a pledge by the Ontario government to probe possible MedsCheck program abuses.
